Table 1.
Demographics of patients in the CS, PESA or TESE treatment groups
| CS (n = 27) | PESA (n = 29) | TESE (n = 37) | P value | |
|---|---|---|---|---|
| Female age | 34.1 ± 3.9 | 35.6 ± 5.0 | 34.6 ± 4.3 | NS |
| AMH (ng/ml) | 2.3 ± 1.7 | 2.6 ± 2.2 | 2.5 ± 2.1 | NS |
| FSH dose (mIU/ml) | 2513 ± 1290 | 2550 ± 1685 | 2041 ± 940 | NS |
| Peak estradiol (pg/ml) | 2282 ± 1016 | 1927 ± 1196 | 2194 ± 1001 | NS |
| No. cycles | 1.07 ± 0.27 | 1.45 ± 0.78 | 1.49 ± 0.60 | 0.001b 0.01c |
| Male age | 36.6 ± 7.1 | 43.7 ± 9.3 | 39.1 ± 8.2 | 0.04a 0.001c |
| Azoospermia diagnosis | na | 16 s/p vasectomy | 6 s/p vasectomy | |
| 1 ejaculatory duct obstruction | 2 epididymal obstruction | |||
| 7 CBAVD | 1 Klinefelter | |||
| 5 idiopathic | 1 trauma | |||
| 27 idiopathic | ||||
| Hormone profile | ||||
| LH (mIU/ml) | na | na | 11.1 ± 9.2 | |
| FSH (mIU/ml) | 16.4 ± 15.3 | |||
| Testosterone (ng/dl) | 498.3 ± 284.3 | |||
aTESE vs PESA bTESE vs CS cPESA vs C TESE for non-obstructive azoospermia (n = 26). P value < 0.05 considered to be statistically significant